04164nam#a2200553#cc4500 990227711990206441 DE-605 20240902214631.0 cr#||||||||||| 190207|2018####au #####o#####|||#|#eng#c 10.4126/FRL01-006413679 doi (DE-605)HT019963002 (DE-599)HBZHT019963002 38 M ger DE-605 38 M DE-605 rda eng XA-AT DE-98 DE-38M 610 615 330 Price comparison of high-cost medicines ... 2017 / authors: Peter Schneider, Sabine Vogler, Nina Zimmermann, Martin Zuba ; project assistent: Ingrid Freiberger, Monika Schintlmeiste ; commissioned by the Federal Ministry of Labour, Social Affairs, Health and Consumer Protection owner, editor und publisher: Gesundheit Österreich GmbH (Austrian Public Health Institute) July 2018 1 Online-Ressource (IX, 16 Seiten) Diagramme, Karten Text txt rdacontent Computer c rdamedia Online-Ressource cr rdacarrier Open Access Unrestricted online access star AIM: The study aims to analyse Austrian prices of high-cost medicines in comparison to other European Union (EU) Member States. METHODS: Medicine price data of all 28 EU Member States were collected through the Pharma Price Information (PPI) service maintained by the Austrian Public Health Institute. Data were surveyed as of September 2017. The survey included 100 high-cost medicines in Austria that were selected based on information about top-selling medicines provided by the Main Association of Austrian Social Security Institutions (outpatient sector) and the Board of the Austrian Association of Hospital Pharmacists (inpatient sector). Ex-factory prices were analysed for all 100 selected medicines. In addition, analyses of further price types (pharmacy purchasing price and pharmacy retail price) were performed for the 60 outpatient medicines surveyed. RESULTS: At the ex-factory price level, price data were available for 82 percent and 69 percent of all surveyed medicines administered in the outpatient and inpatient sector, respectively, in the 27 analysed countries (Malta was excluded due to insufficient data availability). Compared to the other EU Member States, 80 percent of Austrian ex-factory prices of surveyed medicines were above the median. Overall, they were 4.4 percent above the average of the EU Member States, however differences between the two sectors were observed (0.5% above the EU average in the outpatient sector and 10.3% above the EU average in the inpatient sector). Austrian ex-factory prices were the lowest for a few of the analysed high-cost medicines in the outpatient sector, whereas they were never the lowest in the inpatient sector. (...) medicine price pharmaceutical pricing international price comparison Austria Bericht (DE-588)4128022-2 gnd-content Schneider, Peter (DE-588)1177267225 aut Verfasser Vogler, Sabine (DE-588)118137927X aut Verfasser Zimmermann, Nina (DE-588)1181380804 aut Verfasser Zuba, Martin (DE-588)1181348978 aut Verfasser Freiberger, Ingrid (DE-588)1181381983 ctb Mitwirkender Schintlmeister, Monika (DE-588)1177269252 ctb Mitwirkender Österreich Bundesministerium für Arbeit, Soziales, Gesundheit und Konsumentenschutz (DE-588)1155845714 pat Auftraggeber Gesundheit Österreich GmbH (DE-588)10147266-3 isb Herausgebendes Organ (DE-600)2967641-1 2017 https://jasmin.goeg.at/id/eprint/428 Langzeitarchivierung kostenfrei Volltext https://repository.publisso.de/resource/frl:6413679 Volltext Archivierte Online-Ressource 990227711990206441 DE-98 NRW d 990227711990206441 DE-38M NRW d iall OA 38 M: ellinet ; GND: (DE-588)10147266-3